Evogene Ltd (EVGN) FinancialsEVGNEvogene Ltd

Evogene Ltd (EVGN) generates its revenue primarily from Agricultural Crops, which accounts for 100.0% of total sales, equivalent to $4.41M. Understanding this concentration is critical for investors evaluating how EVGN navigates market cycles within the Biotechnology & Medical Research industry.

Evaluating the bottom line, Evogene Ltd maintains a gross margin of 40.63%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at -703.46%, while the net margin is -458.50%. These profitability ratios, combined with a Return on Equity (ROE) of -5796.49%, provide a clear picture of how effectively EVGN converts its operational activities into shareholder value.

In the context of the broader market, EVGN competes directly with industry leaders such as CODX and XCUR. With a market capitalization of $9.49M, it holds a leading position in the sector. When comparing efficiency, EVGN's gross margin of 40.63% stands against CODX's -48.76% and XCUR's N/A. Such benchmarking helps identify whether Evogene Ltd is trading at a premium or discount relative to its financial performance.

Evogene's total revenue for Q2 2026 was $347,000, with a gross margin of 40.63%. The company has shown a significant improvement in net loss, reducing it by 62% year-over-year, but still faces substantial financial hurdles.